(Alliance News) - BiVictriX Therapeutrics PLC announced on Monday that it had received positive final data from a second in vivo efficacy study of BVX001, an antibody drug for treatment of acute myeloid leukaemia.

The Macclesfield, England-based biotechnology company focusing on cancer therapies said that at day 28, BXC001 induced "highly statistically significant tumour regressions" of 97% in an efficacy study of acute myeloid leukaemia.

This followed the interim efficacy study on 19 June which indicated an 89% tumour regression at day 18 following six out of the total eight planned doses of BVX001.

Chief Executive Officer Tiffany Thorn said: "I am delighted to announce that BVX001 continued to deliver highly statistically significant tumour regressions in this model.

"This is very encouraging data, as many anti-cancer agents perform less favourably in larger tumours, due to reduced drug penetration. These strong results demonstrate that BVX001 retains its potent anti-tumour activity even in a more difficult setting."

BiVictriX also announced that the United States Patent & Trademark Office had issued a notice of allowance, agreeing to issue a patent which protects BVX001 in the US. The company said it anticipates that the patent claims will be granted in the US within the coming months.

Shares in Bivictrix Therapeutics were flat at 14.40 pence in London on Monday afternoon.

By Will Neill, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved